Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

New_FDA_Approval!

FDA approves longer-acting calaspargase pegol-mknl for ALL

On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute...
New_FDA_Approval!

FDA approves olaparib for first-line maintenance of BRCA-mutated advanced ovarian cancer

FDA approves olaparib for first-line maintenance of BRCA-mutated advanced ovarian cancer On December 19, 2018, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the maintenance treatment...
New_FDA_Approval!

FDA approves Herzuma as a biosimilar to Herceptin (for breast cancer)

FDA approves Herzuma as a biosimilar to Herceptin On December 14, 2018, the Food and Drug Administration approved Herzuma (trastuzumab-pkrb, Celltrion Inc.) as a biosimilar to Herceptin (trastuzumab, Genentech Inc.)...
Matt_Tribute

SURVIVEiT Mourns Death of Founder and Former CEO Matt J. Ellefson

FOR IMMEDIATE RELEASE Contact: info@surviveit.org December 5, 2018 SURVIVEiT Mourns Death of Founder and Former CEO Matt J. Ellefson SIOUX FALLS, SD. (Dec. 5, 2018) – Cancer warrior and advocate, Matt...
Matt_Tribute

Rest in Love, our Fearless Leader

These words won’t do Matt Ellefson justice, but it’s the best I can do in the midst of such a monumental loss. Matt’s tenacity (spiritual, physical and emotional), integrity and...
New_FDA_Approval!

FDA approves Vitrakvi based on shared mutation rather than a specific type of tumor

FDA approves ‘precision medicine’ drug for different cancers with same mutation By Laurie McGinley Laurie McGinley November 26 The Food and Drug Administration on Monday approved a drug for a wide...
New_FDA_Approval!

FDA approves gilteritinib for relapsed or refractory AML with a FLT3 mutation

FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation On November 28, 2018, the Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US...
New_FDA_Approval!

FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin’s lymphoma

FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin’s lymphoma On November 28, 2018, the Food and Drug Administration approved Truxima (rituximab-abbs, Celltrion Inc.) as the first biosimilar to Rituxan...
New_FDA_Approval!

FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma

FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma On November 9, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients...
New_FDA_Approval!

FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL

FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL On November 16, 2018, the Food and Drug Administration approved brentuximab vedotin (ADCETRIS, Seattle Genetics Inc.) in combination with...
New_FDA_Approval!

FDA approves glasdegib for AML in adults age 75 or older or who have comorbidities

FDA approves glasdegib for AML in adults age 75 or older or who have comorbidities On November 21, 2018, the Food and Drug Administration approved glasdegib (DAURISMO, Pfizer Labs) in...
Progress!_

Groundbreaking Results With Pembrolizumab Plus Surgery in Bladder Cancer

Groundbreaking Results With Pembrolizumab Plus Surgery in Bladder Cancer by Dave Levitan Nov 19, 2018 Neoadjuvant pembrolizumab was safe to administer and resulted in a significant proportion of patients with...